Trading in Novo Nordisk shares by board members, executives and associated persons
May 06 2024 - 3:02PM
Trading in Novo Nordisk shares by board members, executives and
associated persons
Bagsværd, Denmark, 06 May 2024 – This company
announcement discloses the data of the transaction(s) made in Novo
Nordisk shares by the company’s board members, executives and their
associated persons in accordance with Article 19 of Regulation No.
596/2014 on market abuse.
The company’s board members, executives and their associated
persons have given Novo Nordisk power of attorney on their behalf
to publish trading in Novo Nordisk shares by the company’s board
members, executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
1 Details of the person discharging
managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonNovo
Holdings A/S, associated to Kasim Kutay2
Reason for the notification
a)Position/statusMember of the Board of Directorsb)Initial
notification/AmendmentInitial notification3
Details of the issuer
a)NameNovo Nordisk
A&Sb)LEI549300DAQ1CVT6CXN3424 Details
of the transaction(s)
a)Description of the financial instrument, type of instrument,
Identification codeShares
Novo Nordisk B DK0062498333b)Nature of the transactionSale of
sharesc)Price(s) and volume(s)
|
|
|
|
Price(s) |
Volume(s) |
|
DKK 860.02 |
6,311,250 shares |
|
|
|
d)Aggregated information
6,311,250 sharesDKK 5,427,801,225.00e)Date of the
transaction2024-05-06f)Place of the transactionOutside a trading
venue
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 66,000 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contacts for further information
|
Media: |
|
| Ambre
James-Brown +45 3079 9289abmo@novonordisk.com |
Liz
Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com |
|
Investors: |
|
| Daniel
Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com |
Jacob
Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
| David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
| Sina
Meyer +45 3079 6656 azey@novonordisk.com |
Frederik
Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
| Ida
Melvold Gjøsund +45 3077 5649 idmg@novonordisk.com |
|
Company announcement No 39 / 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
From Apr 2024 to May 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
From May 2023 to May 2024
